title: Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation.
abstract: Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the potential for neuropsychiatric events. The costs associated with varenicline are offset by direct savings associated with the reduction in smoking-related diseases. Indeed, despite their limitations, available pharmacoeconomic analyses from numerous countries support the use of varenicline for 12 or 24 weeks as a cost-effective treatment relative to other smoking cessation therapies in smokers who wish to quit smoking. For example, in modelled cost-effectiveness analyses conducted from a healthcare payer perspective, 12 weeks' treatment with varenicline consistently dominated bupropion sustained release and nicotine replacement therapy, and was dominant over, or considered cost effective relative to, unaided cessation, brief counselling or nortriptyline, with regard to the incremental costs per quality-adjusted life-year or life-year gained.
authors.affiliation: Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Lyseng-Williamson
mesh_terms: D001552:Benzazepines; D003362:Cost-Benefit Analysis; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D018722:Nicotinic Agonists / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D011810:Quinoxalines; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods; D014029:Tobacco Use Disorder / Q000188:drug therapy / Q000191:economics*; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D000068580:Varenicline
references.citation: Expert Rev Pharmacoecon Outcomes Res. 2009 Jun;9(3):257-64
references.pmid: 19527098
references.citation: Clin Drug Investig. 2009;29(10):655-65
references.pmid: 19715382
references.citation: Pharmacoeconomics. 2008;26(6):497-511
references.pmid: 18489200
references.citation: Clin Ther. 2007 Jun;29(6):1040-56
references.pmid: 17692720
references.citation: Vasc Health Risk Manag. 2008;4(4):837-45
references.pmid: 19066000
references.citation: Pharmacotherapy. 2007 Nov;27(11):1550-7
references.pmid: 17963463
references.citation: BMJ. 2004 Jan 24;328(7433):217-9
references.pmid: 14739193
references.citation: Curr Med Res Opin. 2008 Jan;24(1):51-61
references.pmid: 18021492
references.citation: Am J Health Behav. 2008 Nov-Dec;32(6):664-75
references.pmid: 18442345
references.citation: JAMA. 2006 Jul 5;296(1):47-55
references.pmid: 16820546
references.citation: MMWR Morb Mortal Wkly Rep. 2008 Nov 14;57(45):1226-8
references.pmid: 19008791
references.citation: Respir Med. 2008 May;102(5):699-710
references.pmid: 18289839
references.citation: Curr Med Res Opin. 2010 Mar;26(3):549-60
references.pmid: 20050814
references.citation: Prev Chronic Dis. 2009 Jul;6(3):A84
references.pmid: 19527585
references.citation: Tob Control. 2004 Dec;13(4):388-95
references.pmid: 15564623
references.citation: JAMA. 2006 Jul 5;296(1):64-71
references.pmid: 16820548
references.citation: J Eval Clin Pract. 2009 Jun;15(3):478-85
references.pmid: 19536915
references.citation: Value Health. 2010 Mar-Apr;13(2):209-14
references.pmid: 19912599
references.citation: An Med Interna. 2008 Jul;25(7):342-8
references.pmid: 19295994
references.citation: Pharmacoeconomics. 2010;28(3):231-54
references.pmid: 20108995
references.citation: Eur J Public Health. 2009 Dec;19(6):650-4
references.pmid: 19491286
references.citation: Am J Med. 2008 Apr;121(4 Suppl 1):S32-42
references.pmid: 18342165
references.citation: Thorax. 2008 Aug;63(8):717-24
references.pmid: 18263663
references.citation: Pharmacoeconomics. 2009;27(3):247-61
references.pmid: 19354344
references.citation: JAMA. 2006 Jul 5;296(1):56-63
references.pmid: 16820547
references.citation: Manag Care Interface. 2007 Oct;20(10):18-25
references.pmid: 18405203